基于胱抑素C的危重症患者急性肾损伤分期系统的开发与验证
本研究在9424例瑞典危重症患者中,将KDIGO肌酐标准分期转换为基于胱抑素C的分期,并利用长期死亡率评估模型性能,另用434例独立队列验证。
要点
- 胱抑素C分期较KDIGO肌酐标准多识别11%的AKI和10%的3期。
- 验证队列中胱抑素C上调分期是死亡风险增加的独立预测因子。
核心结论
- 在危重症患者中,基于胱抑素C的分期比KDIGO标准识别出更多AKI,且这些患者短期和长期死亡率增加。
研究设计与样本
- 开发队列纳入3家瑞典医院的9424例危重症患者,随访5.6年(中位IQR 2.8-7.2),验证队列434例。
主要发现
- 胱抑素C分期较肌酐分期多识别11%的AKI和10%的3期。
- 验证队列中胱抑素C上调分期是死亡风险增加的独立预测因子。
关键数值与推荐
- 1期:7天内胱抑素C增至基线1.40-1.59倍或48小时内升高≥0.44 mg/l。
- 2期:胱抑素C增至基线1.60-2.09倍。
- 3期:胱抑素C增至基线2.10倍以上或≥2.80 mg/l。
临床怎么用
- 在危重症患者中可考虑用胱抑素C分期辅助识别肌酐标准漏诊的AKI高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acute kidney injury (AKI) criteria and staging are based on serum creatinine and urine output, but serum cystatin C performs better at estimating glomerular filtration rate (GFR) in critically ill patients. Accordingly, a cystatin C-based AKI staging system was developed and its performance studied in critically ill patients. METHODS: AKI stages according to Kidney Disease: Improving Global Outcomes (KDIGO) creatinine criteria were converted to corresponding cystatin C-based stages using 14-day mortality in 9424 critically ill patients from 3 Swedish hospitals followed for 5.6 years (median interquartile range: 2.8-7.2). Model performance was evaluated using Cox regression on long-term mortality adjusted for age, gender, comorbidities, and unit type. An independent cohort (n = 434) was used for validation. RESULTS: KDIGO stages corresponded to the following: Stage 1: increase in cystatin C 1.40 to 1.59 times baseline within 7 days or ≥ 0.44 mg/l within 48 hours; Stage 2: 1.60 to 2.09 times baseline; and Stage 3: above 2.10 times baseline or ≥ 2.80 mg/l. Cystatin C-based versus creatinine-based staging identified 11% more AKI and 10% more Stage 3. Patients reclassified to AKI by cystatin C from no AKI had a higher risk of death of 1.36 (1.24-1.49), whereas those reclassified vice versa had a lower risk 0.71 (0.56-0.91). These findings were consistent irrespective of infection status for 30-day mortality. In the validation cohort, reclassification to a higher stage by cystatin C was an independent predictor of increased risk of death. CONCLUSION: In critically ill patients, cystatin C-based staging identified more AKI than KDIGO criteria, and these patients had increased short- and long-term mortality.
引用
- Helmersson-Karlqvist J, Byberg L, Ärnlöv J, et al. Development and Validation of a Cystatin C-based Staging of AKI in Critically Ill Patients. Kidney Int Rep. 2026. PMID: 42027556. doi:10.1016/j.ekir.2026.106514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。